Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial.
Bos EM, Binda E, Verploegh ISC, Wembacher E, Hoefnagel D, Balvers RK, Korporaal AL, Conidi A, Warnert EAH, Trivieri N, Visioli A, Zaccarini P, Caiola L, van Wijck R, van der Spek P, Huylebroeck D, Leenstra S, Lamfers MLM, Ram Z, Westphal M, Noske D, Legnani F, DiMeco F, Vescovi AL, Dirven CMF. Bos EM, et al. Mol Cancer. 2023 Aug 10;22(1):129. doi: 10.1186/s12943-023-01835-6. Mol Cancer. 2023. PMID: 37563568 Free PMC article. Clinical Trial.
Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups.
Gerritsen JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, Versyck G, Jessurun CAC, Pruijn KP, Fisher FL, Larivière E, Solie L, Mekary RA, Satoer DD, Schouten JW, Bos EM, Kloet A, Tewarie RN, Smith TR, Dirven CMF, De Vleeschouwer S, Vincent AJPE, Broekman MLD. Gerritsen JKW, et al. Among authors: bos em. Neuro Oncol. 2023 May 4;25(5):958-972. doi: 10.1093/neuonc/noac255. Neuro Oncol. 2023. PMID: 36420703 Free PMC article.
Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Minczeles NS, Bos EM, de Leeuw RC, Kros JM, Konijnenberg MW, Bromberg JEC, de Herder WW, Dirven CMF, Hofland J, Brabander T. Minczeles NS, et al. Among authors: bos em. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1195-1204. doi: 10.1007/s00259-022-06044-9. Epub 2022 Dec 1. Eur J Nucl Med Mol Imaging. 2023. PMID: 36454268
Human brain mapping using co-registered fUS, fMRI and ESM during awake brain surgeries: A proof-of-concept study.
Soloukey S, Collée E, Verhoef L, Satoer DD, Dirven CMF, Bos EM, Schouten JW, Generowicz BS, Mastik F, De Zeeuw CI, Koekkoek SKE, Vincent AJPE, Smits M, Kruizinga P. Soloukey S, et al. Among authors: bos em. Neuroimage. 2023 Dec 1;283:120435. doi: 10.1016/j.neuroimage.2023.120435. Epub 2023 Oct 30. Neuroimage. 2023. PMID: 37914090 Free article.
Preoperative assessment of eloquence in neurosurgery: a systematic review.
Rammeloo E, Schouten JW, Krikour K, Bos EM, Berger MS, Nahed BV, Vincent AJPE, Gerritsen JKW. Rammeloo E, et al. Among authors: bos em. J Neurooncol. 2023 Dec;165(3):413-430. doi: 10.1007/s11060-023-04509-x. Epub 2023 Dec 14. J Neurooncol. 2023. PMID: 38095774 Review.
MRI-Based Assessment of Brain Tumor Hypoxia: Correlation with Histology.
Arzanforoosh F, Van der Velden M, Berman AJL, Van der Voort SR, Bos EM, Schouten JW, Vincent AJPE, Kros JM, Smits M, Warnert EAH. Arzanforoosh F, et al. Among authors: bos em. Cancers (Basel). 2023 Dec 27;16(1):138. doi: 10.3390/cancers16010138. Cancers (Basel). 2023. PMID: 38201565 Free PMC article.
The prevalence and severity of fatigue in meningioma patients and its association with patient-, tumor- and treatment-related factors.
Quach KT, Dirven L, Vingerhoed AM, de Bresser J, Dammers R, Bos EM, Moojen WA, Peul WC, Taphoorn MJB, Zamanipoor Najafabadi AH, van Furth WR. Quach KT, et al. Among authors: bos em. Neurooncol Adv. 2023 May 19;5(1):vdad056. doi: 10.1093/noajnl/vdad056. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37293257 Free PMC article.
51 results